In a study using DNA/RNA-based NGS and RT-PCR on tissues from 153 individuals, researchers found a high concordance rate of 95.16% between NGS and RT-PCR for identifying EML4-ALK fusion in NSCLC patients, suggesting that RNA-based approaches may offer better precision, benefiting clinical applications in NSCLC diagnosis and treatment [142]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.